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     Objective. Dysregulated chemokine signaling contributes to autoimmune 
diseases by facilitating aberrant T-cell infiltration into target tissues, but the 
specific cytokines, receptors, and T-cell populations remain largely unidentified. 
Role of the potent chemokine CXCL12 and its receptor CXCR4 in T-cell 
autoimmune response was examined using alymphoplasia (aly)/aly mice, a 
Sjögren’s syndrome (SS) model.  
     Methods. T-cell phenotypes in the salivary gland of aly/aly mice were 
evaluated using immunological analysis. In vitro migration assay was used to assess 
T-cell migratory activity toward several chemokines. Gene expression of 
chemokine receptors, and transforming growth factor (TGF)β receptors was 
measured with quantitative reverse transcription-polymerase chain reaction. The 
CXCR4 antagonist AMD3100 was administered to the aly/aly mice to evaluate its 
suppressive effect on autoimmune lesions.  
     Results. Effector memory T (TEM) cells derived from aly/aly mice 
demonstrated higher in vitro migratory activity toward CXCL12 than aly/+ TEM 
cells. CXCL12 expression was specifically upregulated in the SS target cells of 
aly/aly mice. TEM cells from RelB−/− mice, but not nuclear factor (NF)-κB1−/− mice, 
also showed high migratory activity toward CXCL12, implicating a nonclassical 
NF-κB2/RelB pathway in the regulation of TEM cell migration. TEM cells from 
aly/aly mice also overexpressed TGFβ receptors I and II. The CXCR4 antagonist 
AMD3100 suppressed autoimmune lesions in aly/aly mice by reducing TEM cell 
infiltration.  
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     Conclusion. Our results suggest that the NF-κB2/RelB pathway regulates 
T-cell migration to autoimmune targets through TGFβ/TGFβR-dependent 
regulation of CXCL12−CXCR4 signaling. This suggests that these signaling 
pathways are potential therapeutic targets for treating autoimmune diseases.  
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INTRODUCTION 
       Chemokines are important activators of adhesion molecules and drivers of 
lymphocyte migration to inflammatory sites, including autoimmune lesions. Activated 
or autoreactive T cells derived from naïve T cells migrate to and attack self-tissue or 
cells in the initiation of autoimmunity (1,2). T-cell migration, differentiation, and 
effector activity are controlled by several chemokines, including CXCL9, CXCL10, 
CXCL11, and CXCL12 (2-6). However, as T cells dynamically express multiple 
chemokine receptors and chemokine binding overlaps among these receptors, the 
precise mechanisms of T-cell regulation by chemokine/receptor signaling remain 
unclear. 
         Among these chemokines, CXCL12 is a critical regulator of tissue 
homeostasis, immune surveillance, and inflammatory responses (7). CXCL12 can bind 
to two receptors on T cells, CXCR4 and CXCR7. Moreover, CXCR7 directly modulates 
CXCR4 signaling via CXCR7−CXCR4 hetrodimerization (7). When CXCL12 binds to 
CXCR4 on T cells, CXCR4 heterodimerizes with the T-cell receptor to stimulate 
multiple phospholipase C isoforms, increasing intracellular calcium concentration and 
activating the extracellular signal-regulated kinase pathway, thereby initiating the 
transcription of genes associated with specific T-cell functions (8). In cancer cells, 
expression of CXCR4 and CXCR7 is regulated by nuclear factor (NF)-κB (9), but it is 
unclear how cytokine receptor expression in peripheral T cells is controlled.  
       NF-κB plays a key role in the regulation of many inflammatory processes of 
immune cells (10). The NF-κB family consists of five subunits: NF-κB1 (p105−p50), 
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NF-κB2 (p100−p52), RelA (p65), RelB, and c-Rel. Hetero- or homo-dimers of these 
subunits can be translocated into the nucleus to bind κB sequences neighboring target 
genes (11). Two NF-κB signaling pathways exist in the immune cells, a “classical” 
pathway initiated by the NF-κB1−RelA complex, and an alternative “nonclassical” 
pathway initiated by the NF-κB2−RelB complex (11). The importance of 
NF-κB-inducing kinase (NIK) in NF-κB activation has been demonstrated in studies 
using NIK-deficient and alymphoplasia (aly)/aly mice (12-15). 
       The aly/aly mice carry a mutation in the NIK/mitogen-activated protein kinase 
kinase kinase 14 (MAP3K14) gene. NIK/MAP3K14 is key in regulating the processing 
of p100 to p52 through IKKα in hematopoietic cells (12-15). In addition, the aly/aly 
mouse exhibits autoimmune lesions in the lacrimal and salivary glands, resembling 
those observed in patients with Sjögren’s syndrome (SS) (16). We previously reported 
that the abnormal activation of naïve T cells, but not effector memory T (TEM) cells, in 
aly/aly mice contributes to the onset of autoimmunity due to impaired crosstalk between 
the NF-κB subunits (17). However, the precise role of NIK in TEM cell function still 
remains unclear. In particular, although the chemokine-dependent migration of TEM 
cells to the target organs of autoimmunity via the NF-κB2 signaling pathways, 
including NIK, is a key mechanism in the development of autoimmunity, but the precise 
contribution of NIK remains to be explored.  
      The heterogeneity of memory T cells depends on surface molecule expression 
profile, effector function, signal transduction, and location (18,19). Three distinct 
subsets of memory T cells have been identified: central memory T cells, TEM cells, and 
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memory stem T cells (20). Central memory T cells express CD62L (L-selectin) and 
CCR7 (20), whereas TEM cells do not (20,21). The precise migratory function of TEM 
cells to the target organ in autoimmunity needs to be explored. 
         In the present study, we focused on the migratory response of T cells to 
chemokines in aly/aly mice and the molecular mechanism underlying the expression of 
chemokine receptors. Our results indicate a yet unreported role of NF-κB2 signaling in 
TEM cell function, to our knowledge, and in the pathogenesis of autoimmune diseases. 
     
MATERIALS AND METHODS 
       Mice. The aly/aly and aly/+ mice were obtained from CLEA Japan. NF-κB1−/− 
and RelB−/− mice were obtained from the Jackson Laboratory. The genetic background 
of their mice is C57BL/6J. The mice were housed in a pathogen-free environment 
within the animal facility in Tokushima University. Mice that were 6−16 weeks of age 
were used in the study, and all animal experiments were conducted according to the 
Fundamental Guidelines for Proper Conduct of Animal Experiment and Related 
Activities in Academic Research Institutions under the jurisdiction of the Ministry of 
Education, Culture, Sports, Science and Technology of Japan. The protocol was 
approved by the Committee on Animal Experiments of the University of Tokushima 
and Biological Safety Research Center (Permit Number: T27-7). All experiments were 
performed after administering anesthesia, and all efforts were made to minimize 
suffering. 
       Histological analysis. Salivary and lacrimal glands (SGs and LGs) were 
 7 
harvested from the mice, were fixed in 10% phosphate-buffered formaldehyde (pH 7.2), 
and were prepared for histological examination by staining with hematoxylin and eosin 
(H&E). 
       Immunofluorescence staining and immunohistochemistry. Frozen sections of 
SG tissue were fixed with methanol/acetone (1:1), blocked using an avidin/biotin 
blocking kit (Vector Laboratories, Inc.) and 5% bovine serum albumin, and stained with 
biotinylated anti-mouse CD4 monoclonal antibody (mAb) (eBioscience, RM4.5), with 
Alexa fluoro-546 streptavidin (Invitrogen) as the second Ab. In addition, to detect 
CXCL12 expression in frozen LG tissues, anti-CXCL12 polyclonal Ab (anti-SDF1α, 
Abcam), phycoerythrin (PE)-conjugated ant-mouse EpCAM (CD326) mAb 
(eBioscience, G8.8), PE-conjugated anti-CD45.2 mAb (BioLegend, 104), and 
biotin-conjugated anti-PE mAb (eBioscience, eBioPE-DLE) as the second Ab. After 
washing three times with PBS, nuclear DNA was stained with 
4′,6-diamidino-2-phenylindole dihydrochloride (DAPI) (Invitrogen). The sections were 
observed using a PASCAL confocal laser-scanning microscope (LSM: Carl Zeiss) at a 
magnification of 400 or 630×. LSM image browser version 3.5 (Carl Zeiss) was used 
for image acquisition. For immunohistochemical analysis, paraffin-embedded sections 
using the tissues fixed in 10% phosphate-buffered formaldehyde (pH 7.2) were stained 
with anti-CXCL12 polyclonal Ab (Abcam) using the biotin−avidin immunoperoxidase 
complex reagent (Dako) and 3,3′-diaminobenzidine (DAB) chromogen (Dako). The 
nuclei were counterstained with hematoxylin. 
       Enzyme-linked immunosorbent assay (ELISA). Serum concentration of 
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CXCL12 in B6, aly/+, and aly/aly mice was measured using mouse CXCL12/stromal 
cell-derived factor-1 (SDF-1)α Quantikine ELISA kit (R&D Systems Inc.). 
       Cell isolation. Spleen cells were suspended by homogenization and red blood 
cells were removed with 0.83% ammonium chloride. The remaining cells were washed 
twice with 2% fetal bovine serum/Dulbecco’s modified Eagle’s medium. CD44high 
CD62L− TEM and CD44lowCD62L+ naïve CD4+ T cells were isolated using a cell sorter 
(JSAN Jr Swift, Bay Bioscience) as shown in Supplementary Figure 1. The isolated 
cells were confirmed by the C-C chemokine receptor (CCR)7 expression (CCR7− for 
TEM cells, CCR7low for naïve cells) (Supplementary Figure 1). Lymphocytes 
infiltrating into the target organs were isolated by dispersing LG and SG tissues with 1 
mg/ml collagenase solution (Wako), followed by a density-gradient centrifugation using 
Histopaque-1083 (Sigma-Aldrich). 
      Flow cytometric analysis. Lymphocytes from spleen and target organs were 
stained using antibodies against PE-Cy7-conjugated anti-mouse CD4 mAb (TONBO 
Biosciences, GK1.5), FITC-conjugated anti-mouse CD8 mAb (eBioscience, 53-6.7), 
PE-Cy5.5-conjugated anti-mouse CD44 mAb (TONBO Biosciences, IM7), 
APC-Cy7-conjugated anti-mouse CD62L mAb (BioLegend, Mel-14), PE-conjugated 
anti-mouse/human CXCR7 mAb (BioLegend, 8F11-M16), biotinylated anti-mouse 
CXCR4 mAb (eBioscience, 2B11), biotinylated anti-mouse CCR7 mAb (eBioscience, 
4B12), APC-conjugated anti-mouse transforming growth factor β receptor I (TGFβRI, 
R&D systems, 141231), APC-conjugated anti-mouse TGFβRII polyclonal Ab (R&D 
systems), and APC-conjugated streptavidin (eBioscience). A FACScant flow cytometer 
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(BD Biosciences) was used to identify the cell populations according to surface 
expression profile. Data were analyzed using FlowJo FACS Analysis software (Tree 
Star Inc.).  
       In vitro chemotactic migration assay. After serum starvation in RPMI 1640 
medium for 24 h, CD4+ T cells were plated (5 × 105 cells in 350 µl) in the culture plates 
insert (3.0-µm pore size, Merck Millipore). An equal volume of medium containing 
CXCL9, 10, 11, and 12 (0−750 ng/ml; R&D Systems Inc.) was added to the lower 
chamber in 350 µl of RPMI 1640 containing 0.1% BSA, and then the cells were 
cultured for 4 h at 37°C. The number of migrated cells was analyzed by flow cytometry. 
       Quantitative reverse transcription-polymerase chain reaction (qRT-PCR). 
Total RNA was extracted from lymphocytes using the RNeasy mini kit (QIAGEN) and 
subsequently reverse-transcribed into cDNA. Ct values of > 35 cycles were discarded. 
For standardization, the Ct cutoff of all analyses was set at the default setting (0.2). The 
expression of mRNAs encoding CXCR4, CXCR7, CXCL12, TGFβRI, -II, -III, β-actin, 
and glycerol-3-phosphate dehydrogenase (GAPDH) was determined using a PTC-200 
DNA Engine Cycler (Bio-Rad Laboratories) with SYBR Premix Ex Taq reagent 
(Takara Bio Inc.). The primer sequences used were as follows: CXCR4, forward, 
5`-TCAGTGGCTGACCTCCTCTT-3` and reverse, 
5`-TTTCAGCCAGCAGTTTCCTT-3` CXCR7, forward, 
5`-GGTCAGTCTCGTGCAGCATA-3` and reverse, 
5`-GTGCCGGTGAAGTAGGTGAT-3`, CXCL12: forward, 
5`-CTTCATCCCCATTCTCCTCA-3` and reverse, 
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5`-GACTCTGCTCTGGTGGAAGG-3`, TGFβ receptor I (TGFβRI): forward, 
5′-AACTGAAACACCGTGGGAAC-3′ and reverse, 
5′-TGGGAAGCTTTCAGTTGACC-3′; TGFβRII: forward, 
5′-CCCAGTCTGGAAATGAAAGC-3′ and reverse, 
5′-ACTTTTGTCGTGGGTTCTGG-3′; TGFβRIII: forward, 
5′-TCAGATTTGTGCCTGTCTCG-3′ and reverse, 
5′-CTGGGTGTTCTGCATTTGTG-3′; β-actin: forward, 
5′-GTGGGCCGCTCTAGGCACCA-3′ and reverse, 
5′-CGGTTGGCCTTAGGGTTCAGGGGGG-3′, GAPDH:         forward,  
5′-TGCACCACCAACTGCTTAC-3′                and             reverse,  
5′-GGATGCAGGGATGATGTTC-3′. To confirm the specificity of the primers, each 
PCR product was electrophoresed on an agarose gel to determine the DNA size (bp), 
and a single band for each product was detected at the expected size. Relative mRNA 
expression of each transcript was normalized against β-actin mRNA. To confirm the 
normalization by β-actin, the mRNA expression of CXCL12 was quantified using 
GAPDH as another housekeeping gene (Supplementary Figure 2B). The triplicates per 
experiment were analyzed. The qRT-PCR experiments were repeated at least three 
times.  
       Administration of AMD3100. The CXCR4 inhibitor AMD3100 
octahydrochloride (5 mg/kg; Sigma) was administered daily to female aly/aly mice from 
8 to 16 weeks of age by intraperitoneal (ip) injection. As a control, PBS was 
administered to aly/aly mice following the same regimen. 
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       Statistical analysis. Means of each group were compared using unpaired 
Student’s t-test. A probability (p) value of < 0.05 was considered statistically 
significant. 
 
RESULTS 
       TEM cells in autoimmune lesions of aly/aly mice. Inflammatory lesions in 
the SG of aly/aly mice were observed from approximately 10 weeks of age as 
previously described (16). Infiltration of mononuclear cells around dilated ducts and the 
destruction or atrophy of acinar cells was found in the SG tissues harvested from 3 
months old aly/aly mice (Figure 1A). Moreover, to evaluate the dysfunction of target 
organs, the flow volume of tear and saliva was measured. The flow in aly/aly mice was 
significantly lower than that in aly/+ mice with respect to the autoimmune lesions in 
target organs (Supplementary Figure 2A). Immunofluorescence analysis revealed that 
CD4+ T cells were the predominant infiltrating cell type (Figure 1B), and flow 
cytometric analysis of isolated SG lymphocytes confirmed that over 80% were CD4+ T 
cells (Figure 1C and D). The number of CD44highCD62L− CD4+ TEM cells was higher 
in the spleen of aly/aly mice than that in the aly/+ mice, while there was no difference 
in the total number of TEM cells (Figure 1E) and in the number and proportion of 
CD44lowCD62L+ naïve CD4+ T cells in the spleen between aly/aly and aly/+ mice 
(Figure 1E and F). By contrast, the number of both TEM and naive T cells in the SG 
increased significantly compared with that in aly/+ mice (Figure 1F). 
       Enhanced migratory response of aly/aly mouse CD4+ T cells to CXC 
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chemokines. To examine whether the facilitation of migratory activity contributes to 
TEM cell infiltration observed in aly/aly mice, the migratory response of CD4+ T cells 
isolated from aly/aly and aly/+ mouse spleen toward CXCL9, 10, 11, and 12 was 
evaluated by in vitro transwell migration assay. The migratory rates of aly/aly CD4+ 
TEM cells toward CXCL12 were significantly higher than those of aly/+ TEM cells, 
while there was no difference in the migratory response to CXCL9, 10, and 11 (Figure 
2A). Furthermore, the response increased with CXCL12 concentration (Figure 2C). In 
contrast, no migratory response toward any of these cytokines was observed with 
respect to naïve CD4+ T cells isolated form aly/aly and aly/+ mouse spleen (Figure 2B 
and D). 
       Elevated CXCL12 expression in target tissues of aly/aly mice. We measured 
serum CXCL12 concentration by ELISA to examine whether higher serum 
concentration contributes to greater TEM cell migration/infiltration in aly/aly mice, but 
found no difference in the B6, aly/+, and aly/aly mice (Figure 3A). We then examined 
whether local accumulation of CXCL12 in the spleen or target organs is responsible for 
this enhanced migratory capacity of aly/aly TEM cells by measuring CXCL12 mRNA 
expression with qRT-PCR. CXCL12 mRNA expression in SGs and LGs of aly/aly mice 
was significantly higher than in aly/+ SGs and LGs (Figure 3B and Supplementary 
Figure 2B), but it was not different in the spleen and lung (Figure 3B). These findings 
suggest that increased CXCL12 expression in the target tissues (SG and LG) contributes 
to the higher TEM cell accumulation and the consequent autoimmune response. It is 
known that increased chemokine levels are detectable in the inflamed tissues of SS 
 13 
patients (22,23), and CXCL12 is ubiquitously expressed in many tissues and cell types 
(7). To determine the cell type producing CXCL12 in the target organs, 
immunofluorescence analysis was performed. CXCL12-expressing cells in target tissue 
of aly/aly mice at 12 weeks of age. EpCAM+ epithelial cells in LGs expressed CXCL12 
in aly/aly, but not aly/+, mice while Ly5.2+ lymphocytes infiltrated in LGs didn’t 
express CXCL12 in aly/aly mice (Figure 3C and D). The CXCL12 expression was                    
found in the epithelial cells neighboring the area of lymphocyte infiltration (Figure 3C, 
D). At 6 weeks of age, when inflammatory lesions were absent, there was no difference 
in the CXCL12 expression in the LGs of aly/aly and aly/+ mice (Supplementary Figure 
2C), suggesting that CXCL12 expression by target cells increases along with the 
migration of inflammatory cells including T cells, and that T-cell migration may further 
increase following the upregulation of CXCL12, leading to the development of severe 
autoimmune lesions. Although the precise mechanism underlying CXCL12 
upregulation in the target organs in aly/aly mice remains unclear, the production might 
be enhanced in the inflammatory lesions of target organs in aly/aly mice. 
       Elevated CXCL12 receptor expression on the TEM cells of aly/aly mice. 
While CXCR4 is the best described CXCL12 receptor, this cytokine also binds to 
CXCR7 (7,24). To examine whether the upregulation of these receptors also contributes 
to enhanced CXCL12-dependent tissue infiltration of TEM cells in aly/aly mice, 
CXCR4 and CXCR7 expression in TEM and naïve T cells isolated from the mouse 
spleen were measured by flow cytometry. Surface expression of CXCR4 on TEM cells 
belonging to the aly/aly mice was significantly higher than that on aly/+ TEM cells, 
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whereas no difference in the expression of CXCR7 was seen (Figure 4A and 
Supplementary Figure 3). By contrast, there was no difference in CXCR7 or CXCR4 
expression on naïve CD4+ T cells between aly/aly and aly/+ mice (Figure 4B). 
Furthermore, mRNA expression of CXCR4 was significantly higher in TEM cells 
isolated from the spleen of aly/aly mice compared with the aly/+ mice, while there was 
no difference in CXCR7 mRNA expression (Figure 4C). No difference in the CXCR7 
and CXCR4 expression in naïve CD4+ T cells was observed between aly/aly and aly/+ 
mice (Figure 4D). These findings suggest that the high migratory activity of TEM cells 
from aly/aly mice toward CXCL12 results from the increased expression of CXCR4. 
       To understand the role of both classical and nonclassical NF-κB pathways in 
the migratory response of TEM cells to CXCL12, the in vitro migratory assay in 
response to CXCL12 was performed using TEM and naïve CD4+ T cells isolated from 
wild-type (WT), NF-κB1 (p50)−/−, aly/aly, and RelB−/− mice. There was no difference in 
the migratory response of TEM cells in WT and NF-κB1−/− mice (Figure 4E). In 
contrast, RelB−/− mice demonstrated a significantly increased migratory response 
without CXCL12 compared with the WT mice (Figure 4E). In addition, the migratory 
response to CXCL12 in RelB−/− mice was significantly higher than that in the WT mice 
(Figure 4E). Moreover, the migratory response to CXCL12 in RelB−/− mice was 
significantly higher than that in the aly/aly mice (Figure 4E). Therefore, TEM cells in 
RelB−/− mice are generally more mobile to chemokines. In accordance with these results, 
no substantial migratory response was observed with respect to the naïve T cells in 
NF-κB1−/−, aly/aly, and RelB−/− mice (Figure 4F). This suggests that the nonclassical 
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NF-κB2/RelB pathway regulates the migratory response to CXCL12 in TEM cells. 
       Role of TGFβ1 in CXCR4 expression by TEM cells. TGFβ is considered as 
the master regulator of T-cell activity, and CXCR4 expression in human T cells is 
controlled by TGFβ1 (25,26). Therefore, we examined whether TGFβ1 signaling is 
involved in CXCR4 overexpression by aly/aly TEM cells. TGFβ1 upregulated the 
expression of CXCR4 mRNA in both aly/aly and aly/+ TEM cells, but the increase was 
greater only in aly/aly TEM cells (Figure 5A). By contrast, no enhancement of CXCR4 
mRNA expression by TGFβ1 was observed in naïve CD4+ T cells of either genotype 
(Figure 5A). Moreover, the protein levels of CXCR4 expression in TEM cells of aly/aly 
mice increased significantly because of TGFβ1, whereas an increase in CXCR4 
expression on TEM cells of aly/+ mice was not observed (Figure 5B). There was no 
change in CXCR4 expression in naïve T cells by TGFβ1 in both aly/aly and aly/+ mice 
(Figure 5B). Consistent with a critical role of CXCL12−CXCR4 signaling during 
increased aly/aly TEM cell migration, the migratory response of aly/aly TEM cells to 
CXCL12 was further upregulated by TGFβ1, compared with aly/+ TEM cells (Figure 
5C). Collectively, these results suggest that NF-κB2 negatively controls CXCR4 
expression through TGFβ signaling.  
       We also investigated whether TGFβ receptor signaling is upregulated in aly/aly 
TEM cells, thereby accounting for the enhanced sensitivity to TGFβ. Indeed, qRT-PCR 
results showed that the expression of TGFβRI and II was significantly higher in aly/aly 
TEM cells than in aly/+ TEM cells (Figure 5D). As expected, there was no difference in 
the expressions by naïve CD4+ T cells in aly/+ and aly/aly mice, again consistent with 
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the lack of TGFβ effects on migration (Figure 5D). There was also no difference in 
TGFβRIII expression in aly/+ and aly/aly TEM cells (Figure 5D). Furthermore, flow 
cytometric analysis revealed that the number of TGFβRI+ TEM cells in aly/aly mice 
was significantly higher than that in aly/+ mice (Figure 5E). The proportion of 
TFGβRII+ TEM cells in aly/aly mice also increased compared with that in aly/+ mice 
(Figure 5F). These findings suggest that NF-κB2 controls the migratory function of 
TEM cells by regulating the TGFβ/TGFβR/CXCR4 signaling axis.     
       Therapeutic effect of CXCR4 inhibitor on autoimmune lesions in aly/aly 
mice. Finally, we examined whether the suppression of migration-promoting signaling 
pathways reduces the autoimmune response in aly/aly mice. Intraperitoneal injection of 
the specific CXCR4 antagonist AMD3100 from 8 to 16 weeks of age dramatically 
reduced autoimmune lesions in SG and LG of aly/aly mice and suppressed lymphocyte 
infiltration into these target organs (Figure 6A and B). Moreover, the proportion of 
TEM cells among all infiltrated lymphocytes in SG and LG was significantly reduced 
by AMD3100 compared with that in the vehicle-treated controls (Figure 6C and D). 
There were no differences in the number of CD3+ T cells, CD19+ B cells, CD4+ T cells, 
and CD8+ T cells in the spleen of mice administered with AMD3100 or vehicle 
(Supplementary Figure 4). This suggests that inhibition of CXCR4 prevents 
autoimmune lesions in aly/aly mice by suppressing CXCL12-induced TEM cell 
migration.           
 
DISCUSSION 
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       In this study, the phenotype of the CD4+ T cells infiltrating into the target 
tissues of aly/aly mice was similar to that of CD44highCD62L−CCR7− CD4+ TEM cells. 
These infiltrating cells are believed to involve autoreactive T cells. Our findings 
strongly suggest that CXCL12 is a critical factor promoting TEM cell infiltration into 
target organs. The migratory response of TEM cells, including autoreactive T cells, was 
markedly enhanced in aly/aly mice compared with aly/+ mice. Several reports have 
demonstrated that chemokines are upregulated in the target organs in patients with SS 
(22,27), and indeed, CXCL12 expression increased in the inflammatory lesions of 
aly/aly mice. Moreover, CXCR4 was also upregulated in the TEM cells of the aly/aly 
mice, thus explaining the strong recruitment of these cells into the target tissues.  
        CXCR4 is one of several chemokine receptors exploited by the human 
immunodeficiency virus (HIV) to infect CD4+ T cells in addition to a major receptor of 
CXCL12, called SDF-1 (28). CXCR4 is widely expressed at high levels in various 
immune cells such as monocytes, B cells, and naïve T cells (5,8,29,30). 
CXCR4-knockout mice are embryonically lethal owing to impaired hematopoiesis, 
organ vascularization, and neuronal migration (29,31). Recent reports have 
demonstrated that blocking the CXCL12−CXCR4 interaction can inhibit tumor growth 
by reducing tumor angiogenesis (5,24). Furthermore, inhibition of the 
CXCL12−CXCR4 pathway in the CD4+ T cells of nonobese diabetes (NOD) mice using 
the specific CXCR4 antagonist AMD3100 can protect against autoimmune diabetes 
(32). Similarly, administration of AMD3100 reduces the severity of autoimmune lesions 
in an experimental autoimmune encephalomyelitis model by reducing the number of 
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immune cells localizing to the perivascular space in response to CXCL12 (33). 
Autoimmune collagen-induced arthritis in IFN-γR-deficient DBA/1 mice was reduced 
in severity by AMD3100 treatment through the inhibition of CXCR4+ macrophage 
migration to target organ (34). Moreover, autoimmune thyroiditis in NOD.H-2h4 mice 
was also suppressed by AMD3100 administration (35). In our study, the autoimmune 
lesions in aly/aly mice were suppressed by AMD3100 administration through the 
inhibition of TEM cell migration to the target organs. Expression of CXCR4 by naïve T 
cells in humans is controlled by TGFβ signaling [26], and we found that CXCR4 
mRNA expression by TEM cells was also enhanced by TGFβ1. Furthermore, the 
enhancement was strong in the TEM cells of aly/aly mice, consistent with the enhanced 
expression of TGFβR. Collectively, these results suggest that NF-κB2 may control 
CXCR4 expression in TEM cells through TGFβ signaling. 
       NIK plays a key role in regulating the processing of p100 to p52 through IKKα 
in both hematopoietic cells and osteoclasts (10,11,36,37). NIK–/– and aly/aly mice lack 
lymph nodes, and, at least for aly/aly mice, the T cells show defective proliferation and 
IL-2 production in response to stimulation by the CD3 antibody (anti-CD3) (13). 
Furthermore, NIK may be involved in the maintenance of central tolerance in the 
thymus (14). Moreover, aly/aly mice and RelB–/– mice show signs of autoimmune 
disease (16,38). Our previous report demonstrated that NF-κB2 controls the classical 
NF-κB pathway in naïve CD4+ T cells by interacting with NF-κB1 (17). In addition, 
overactivation of naïve T cells in aly/aly mice due to impaired interaction with NF-κB2 
results in induction of the autoimmune reaction (17). In the present study, NF-κB2 
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negatively regulated TGFβ signaling in TEM cells, while TGFβ upregulated CXCR4 
expression. It is known that a molecular interaction between NF-κB2 and Smad3 
downstream of TGFβR plays an important role in the transcriptional activity of c-jun 
(39). Further analysis of the molecular mechanisms controlling CXCR4 expression 
through NF-κB2 and TGFβ signaling is necessary for understanding how T cells 
contribute to the pathogenesis of autoimmunity. 
   Therapy for SS is mainly symptomatic, such as sialagogue or moisturizing agents 
for dry mouth, and eye drops for dry eye (40). Cytokine or steroid therapy is often 
effective for some autoimmune diseases such as rheumatoid arthritis. However, a 
radical therapy for SS has not been established. In aly/aly mice, autoimmune lesions 
were promoted both by upregulation of CXCL12 in the target organs and that of 
CXCR4 expression on TEM cells. Further study is required to determine the underlying 
mechanisms for specific CXCL12 overexpression by target tissue but not nontarget 
tissue such as lung. Inhibiting TEM cell function, including that of autoreactive T cells, 
may be a promising in the treatment of autoimmune disease. AMD3100 suppresses the 
growth of several malignant tumors such as prostate cancer and acute myeloid leukemia 
by inhibiting the CXCR4−CXCL12 axis in tumor stroma. (41,42). Our study identifies 
numerous potential molecular targets for such interventions.  
       To summarize, the migratory response of TEM cells to CXCL12 was enhanced 
in aly/aly mice through increased expression of CXCR4 on TEM cells and CXCL12 in 
the target tissues. Upregulation of CXCL12 in SG and LG suggest that target organs 
 20 
contribute to the initiation of autoimmunity. Inhibition of CXCL12−CXCR4 signaling 
in TEM cells could be a useful therapeutic strategy for treating SS. Moreover, CXCR4 
expression is regulated by NF-κB2 through TGFβ signaling, revealing additional targets 
for therapy against autoimmune diseases.  
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Figure legends 
Figure 1. Inflammatory lesions associated with infiltration of effector memory T 
(TEM) cells into the target organs of aly/aly autoimmune model mice (12 weeks). A, 
Inflammatory lesions in the salivary glands (SGs) of female aly/aly mice at 3 months of 
age. Scale bar, 50 µm. B, Accumulation of CD4+ T cells in the SGs of aly/aly mice as 
detected using immunofluorescence staining. Scale bar, 20 µm. The photos are 
representative of each group. C, CD4+ and CD8+ subsets of lymphocytes infiltrated into 
the SGs of aly/aly and aly/+ mice as detected by flow cytometry. D, Number of CD4+ 
and CD8+ T cells among the infiltrated lymphocytes in the SGs of aly/aly and aly/+ 
mice. Data are shown as average ± standard deviation (SD) of six to eight mice per 
group. *p < 0.05. E, CD44/CD62L expression in CD4+ T cells in the spleen and SGs of 
aly/aly and aly/+ mice as detected using flow cytometry. The results are representative 
of each group. F, Numbers of CD44highCD62L− TEM and CD44lowCD62L+ naïve CD4+ 
cells in the spleen and SGs of aly/aly and aly/+ mice. Data are shown as average ± SD 
of six to eight mice per group. *p < 0.05. 
 
Figure 2. Enhanced migratory rate of TEM cells toward CXCL12 isolated from aly/aly 
mice (12 weeks). A, Chemotactic activities of TEM cells in the presence of CXCL9, 10, 
11, and 12 (all 750 ng/ml) were analyzed by in vitro migration assay with transwell 
membranes (3 µm). The data are expressed as average ± SD of triplicates, and are 
representative of three independent experiments. *p < 0.05. B, Chemotactic activity of 
naïve CD4+ T cells in the presence of CXCL9, 10, 11, and 12. C, Dose-dependent 
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migratory response of CD4+ TEM cells to CXCL12 (250, 500, and 750 ng/ml) in aly/aly 
mice. Data are shown as average ± SD of triplicates and are representative of three 
independent experiments. *p < 0.05. D, Migratory response of naïve CD4+ T cells to 
CXCL12. All data presented as average ± SD of three independent experiments 
conducted in triplicate.  
 
Figure 3. CXCL12 overexpression in target tissues of aly/aly mice (16 weeks). A, 
CXCL12 concentration in sera from B6, aly/+, and aly/aly mice as determined by 
ELISA. Data are shown as average ± SD of four mice per group. B, CXCL12 mRNA 
expression levels in the spleen, SG, LG, and lung as analyzed by qRT-PCR. Data are 
shown as average ± SD of five mice per group. *p < 0.05. C, CXCL12 expression in 
LGs in aly/aly and aly/+ mice as detected by immunofluorescence analysis using 
Alexa-546-conjugated anti-EpCAM mAb and Alexa-488-conjugated anti-CXCL12 
mAb. The nuclei were stained with DAPI. The results were representative of five mice 
per group. Scale bar, 10 µm. Lymphocyte (Ly) infiltrating area was separated from 
epithelial cell (Ep) area by white dot line. D, Immunofluorescence analysis of LGs was 
performed with Alexa-546-conjugated anti-Ly5.2 mAb and Alexa-488-conjugated 
anti-CXCL12 mAb. The nuclei were stained with DAPI. The results were representative 
of five mice per group. Scale bar, 10 µm. Ly infiltrating area was separated from Ep 
area by white dot line. The results were representative of five mice per group. 
 
Figure 4. Overexpression of CXCR4 and CXCR7 in aly/aly TEM cells. A and B, Cell 
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surface expression of CXCR7 and CXCR4 in TEM cells (A) and naïve (B) CD4+ T cells 
from the spleen of aly/aly and aly/+ mice (10 weeks) was detected by flow cytometry. 
Expression relative to isotype control detected as mean fluorescence intensity (MFI) and 
presented as average ± SD of five mice per group. *p < 0.05. C and D, mRNA 
expression of CXCR7 and CXCR4 in TEM (C) and naïve (D) CD4+ T cells in the 
spleen of aly/+ and aly/aly mice as analyzed by qRT-PCR. Data are shown as average ± 
SD of seven mice per group. *p < 0.05. E and F, Migratory response to CXCL12 (750 
ng/ml) of TEM (E) and naïve (F) CD4+ T cells in the spleen of WT, NF-κB1−/−, aly/aly, 
and RelB−/− mice (10 weeks). Data are shown as average ± SD of three independent 
experiments conducted in triplicate. *p < 0.05, **p < 0.05.  
 
Figure 5. Enhanced CXCL12-induced migration of TEM cells by activation of TGFβ 
signaling. A, CD4+ TEM and naive CD4+ T cells of aly/aly and aly/+ mice (10−12 
weeks) were stimulated with TGFβ1 (0.125 ng/ml) for 24 h. CXCR4 mRNA expression 
determined by qRT-PCR. Data are shown as average ± SD of five mice per group. *p < 
0.05, **p < 0.005. B, Cell surface expression of CXCR4 in TEM and naïve CD4+ T 
cells from the spleen of aly/aly and aly/+ mice was detected by flow cytometry. 
Expression relative to isotype control detected as MFI and presented as average ± SD of 
five mice per group. *p < 0.05, **p < 0.005. C, TEM cells from aly/aly and aly/+ mice 
were stimulated with TGFβ1 (0.125 ng/ml) or sham-treated for 24 h and the migratory 
response to CXCL12 (750 ng/ml) as analyzed by in vitro migration assay. Data are 
shown as average ± SD of three independent experiments conducted in triplicate. *p < 
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0.05. D, mRNA expression of TGFβRI, II, and III in naïve and TEM cells from aly/aly 
and aly/+ mice were determined by qRT-PCR. Data are shown as average ± SD of five 
mice per group. *p < 0.05. E, TGFβRI+ TEM and naïve CD4+ T cells were analyzed by 
flow cytometry. Data are shown as average ± SD of five mice per group. **p < 0.005. F, 
TGFβRII+ TEM and naïve CD4+ T cells were analyzed by flow cytometry. Data are 
shown as average ± SD of five mice per group. *p < 0.05. 
 
Figure 6. Therapeutic effect of a CXCR4 inhibitor on autoimmune lesions in aly/aly 
mice. The CXCR4 inhibitor (AMD3100, 5 mg/kg) was intraperitoneally injected daily 
into aly/aly mice from 8 to 16 weeks of age. A and B, Paraffin-embedded sections of 
SG (A) and LG (B) from control and AMD3100-administered mice stained with H&E. 
Photos are representative of five mice for each group. Scale bar: 50 µm. C and D, 
Numbers of TEM and naïve CD4+ T cells among infiltrated lymphocytes in SG (C) and 
LG (D) of control and AMD3100-treated mice were determined by flow cytometry. 
Data are shown as average ± SD of five mice per group. *p < 0.05. 
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